How tumor and patient factors affect GEP-NEN treatment response
Part of Cancer clinical trials.
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a well-differentiated (slow-growing) neuroendocrine tumor in your digestive system (pancreas, stomach, intestines, etc.) that is either localized but not removable by surgery, or has spread to nearby areas or other parts of the body.
- You have been treated for at least 6 months with one of these therapies: somatostatin analogs (for low-grade tumors), everolimus or sunitinib (for low- or intermediate-grade), or capecitabine-temozolomide (for intermediate- or higher-grade tumors).
- You have not had radioligand therapy (targeted radiation) before.
- You are not currently receiving other localized treatments (like surgery, radiation, or embolization).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether specific blood “biomarkers” can help confirm a type of cancer called NEN (neuroendocrine neoplasm) and show whether treatment is working early. It may help doctors start or adjust treatment sooner, especially for cancers that are advanced or have spread.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
This trial looks at epigenomic markers in different types of neuroendocrine tumors and cancers to find better ways to diagnose and treat them. It may help if you have a neuroendocrine tumor or certain other gastrointestinal cancers that can be surgically removed or biopsied.
This is a registry study that collects medical information from adults with neuroendocrine tumors (NETs) that start in the digestive organs. It helps researchers understand these cancers better and may support future studies.
This trial is studying well-differentiated high-grade neuroendocrine tumors that start in the thymus, lung, or pancreas. It compares these tumors to understand them better and find better treatments.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.